Alzheimer's drug trials take heat

The conduct of Alzheimer's researchers in clinical trials has come under question, with revelations the results of genetic testing were withheld from participants which throws doubt on whether their consent was truly informed. 

An article in the New York Times (NYT) raises the issue of informed consent of the participants in trials testing two Alzheimer's drugs, Biogen and Eisai's Leqembi and Eli Lilly's Kisunla.

The story focuses on both companies withholding the results of a genetic test for a mutation in the APOE4 gene that increases a person's risk of developing Alzheimer's disease, and also makes them more vulnerable to brain bleeding or swelling if they receive the drug being trialed.